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Abstract
Screening mammography has been shown to be effective for
reducing breast cancer mortality. According to screening theory,
the first expected consequence of mammography screening is the
detection of the disease at earlier stages and this diagnostic
anticipation changes the population incidence curve, with an
observed increase in incidence rates at earlier ages. It is
unreasonable to expect that the age-specific incidence will ever
return to pre-screening levels or to anticipate a significant
reduction of incidence at older ages immediately after the first
screening round. The interpretation of incidence trends, especially
in the short term, is difficult. Methodology for quantification of
overdiagnosis and statistical modelling based on service screening
data is not well developed and few population-based studies are
available. The overtreatment issue is discussed in terms of
appropriateness of effective treatment considering the question of
chemotherapy in very early stages and the use of breast
conserving surgery.
Introduction
The results of eight randomised clinical trials have shown
screening mammography to be effective in reducing breast
cancer mortality [1,2]. Evidence of efficacy was shown for
women aged 50 years and over and service screening was
implemented at national or regional levels in many countries
[2,3]. The challenge today is to evaluate service screening in
Europe to assess the outcome of the programmes [4] in
terms of mortality and disease stage at diagnosis.
The aim of breast cancer screening has been shown to be
achieved by the detection of cancer (in situ or invasive) at an
earlier stage of the natural history of the disease and by the
subsequent use of effective treatment in the early phase of
natural history. According to screening theory, the first
expected consequence of mammography screening,
spontaneous or organised, is the detection of the disease at
earlier stages and this diagnostic anticipation changes the
population incidence curve, with an increase in incidence
rates at earlier ages. The shift of the curve at younger ages is
expected to be more evident at the time of prevalence
screening, but it will also continue over the subsequent
rounds of the screening programme.
This excess in incidence should not be confused with
overdiagnosis. Overdiagnosis has been defined as the
detection of in situ or invasive breast cancers at screening that
would have never clinically surfaced in the absence of
screening. It is the combination of two causes: the natural
history of the disease, that is, the low potential of progression of
certain lesions; and the presence of competing causes of death,
such that the detected disease would not have been diagnosed
in the lifespan of the subject in the absence of screening.
In these terms, overdiagnosis is largely an epidemiological
concept, because there is no marker today to classify a
cancer as a pseudodisease. The possibility of overdiagnosis
is inherent to the process of screening, however, and the
quantification of such overdiagnosis is a current challenge to
the epidemiological community.
Excess incidence
The excess in breast cancer incidence related to service
screening with mammography has been described in several
areas. For example, in Fig. 1, the population-based incidence
in the city of Florence during the first and subsequent rounds
of screening is compared with that of the pre-screening era,
showing the excess for different age groups invited to
screening. The screening epoch from 1990 onwards shows a
higher incidence in the 50 to 69 years age group invited to
screening and a lower incidence in the 75 to 79 age group.
In a recent paper, Zahl et al. [5] presented data comparing
areas with or without service screening in Norway and in
Sweden. They estimated that the incidence of invasive breast
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cancer in women aged 50 to 69 years increased by 54% in
Norway and 45% in Sweden over the study period. They
argued that as there was no corresponding, statistically
significant decline in incidence at 70 to 74 years of age, there
must be substantial overdiagnosis.
In the Norwegian counties in which screening started in
1996, there was no significant increase in incidence before
screening and a subsequent increase in the 50 to 69 years
age group after 1995. In the year 2000 (4 years after the
start), the 70 to 74 years age group showed a non-significant
11% reduction in incidence. It is likely, however, that four
years is insufficient time to see the full reduction in incidence
in the post-screening age groups which are not targets for
service screening. In Sweden, an increase in incidence was
evident during the period 1971 to 1985; nationwide
screening was gradually implemented after 1985. The
incidence was not declining by the year 2000 for women
aged 70 to 74 years, but a statistically significant reduction in
incidence of 12% was shown for ages 75 to 79 years. This
reduction was considered small by the authors, but a
reduction of 12% in this age group represents a substantial
number of the incidence at lower ages, in absolute terms. In
Sweden, service screening has also been offered to 70 to
74 year old women in several areas. Thus, the conclusion of
substantial overdiagnosis from these data may be
unwarranted.
Olsen  et al. [6] compared incidence in three Danish
municipalities providing organised screening programmes
with the rest of Denmark. They found a temporary increase in
incidence corresponding to the first screen, followed by a
return to levels close to those in the pre-screening period in
two of the three municipalities. In the third municipality, a
small area of Copenhagen, the increase corresponded more
to the second round of screening, possibly due to poor
sensitivity at the first. The authors concluded that there was
no serious overdiagnosis.
In the UK, McCann et al. [7] projected pre-screening trends
in incidence into the screening epoch and found an excess
incidence in the early 1990s in the screening 50 to 64 years
age group and a deficit in incidence in the late 1990s in the
65 to 69 years age group. They found that accounting for the
later deficit using the earlier excess was more complete if
ductal carcinoma in situ (DCIS) cases were included.
Both Anttila et al. [8] in Finland and Fracheboud et al. [9] in
the Netherlands observed increased incidences of breast
cancer with the introduction of screening. Both groups noted,
however, that these included underlying increases in
incidence that were taking place in any case. In Finland and
the Netherlands, screening programmes were introduced
gradually and the excess incidence will, therefore, be spread
over several years.
The research reviewed above points to a lead time effect as
being responsible, at least in part, for the excess incidence
observed with screening. This does not rule out
overdiagnosis, which may also be partly responsible for the
excess. The challenge is, therefore, to consider the possible
multiple causes of excess incidence in screened cohorts, and
to estimate the extent of overdiagnosis, taking the other
causes into account.
Quantification of overdiagnosis
One should note first that a fixed, discrete cohort, the kind of
population studied in a randomised clinical trial, is extremely
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different from a dynamic population, where several ageing
cohorts and newcomers are monitored for varying periods of
time. In the HIP study, the cumulative breast cancer incidence
in the control group was observed to catch up with the study
group when screening stopped, and this was confirmed by
statistical modelling [10]. This sort of analysis is not available
in the service screening setting.
The possible reasons for an observed excess of incidence in
the service screening context are:
1. In almost all countries, incidence of breast cancer was
increasing before screening programmes were introduced.
2. There is inevitably a surge in incidence at the time of
introduction of screening, due to the prevalence
screening of a large population. The size of the surge will
depend on how long it takes to complete coverage. Most
of this is composed of anticipated tumours that would
have occurred in any case in the following five years.
3. A continued surge at the lower end of the age range for
screening as the women reaching the lower age limit have
a prevalence screen.
4. There will be a shift in the age-incidence curve due to
lead time. If the screening programme is achieving an
average lead time of three years, say, then we will observe
age 53 incidence at age 50, age 54 incidence at age 51,
and so on.
5. Depending on the temporal pattern of screening activity,
there may also be periodic excesses due to anticipated
tumours from incidence screening, balanced by periodic
deficits in clinical cancer incidence between such screens.
6. There may also be overdiagnosis.
Reason 3 and 4 will remain active as long as the screening
programme is in place. Thus it is unreasonable to expect that
the age-specific incidence will ever return to pre-screening
levels. Also, it should be noted that a deficit in incidence
above the age limits for screening can only occur in cohorts
that have actually been through the screening programme.
One cannot expect, therefore, to observe immediately after
the first round of screening a significant reduction in
incidence at older ages. So the interpretation of incidence
trends, especially in the short term, is difficult.
Methodology for quantification of overdiagnosis is not yet well
developed but there are some examples in the literature. In
the city of Florence, service screening started at the
beginning of 1990, offering high-quality mammography every
2 years to women aged 50 to 69 years. An evaluation of
overdiagnosis due to service screening was performed after
10 years [11]. This compared incidence in the period 1990
to 1999 with that expected in the absence of screening, but
with adjustment for that part of the excess that was due to
lead time alone, and not to overdiagnosis.
All breast cancer cases were partitioned by diagnostic
method (screen detected versus clinically detected).
Considering the mean sojourn time estimate of 3.7 years for
breast cancer cases and an exponential distribution of the
sojourn time, the probability that a screen detected case
would have remained asymptomatic up to the end of the
study period was calculated. The sum of the probabilities of
clinical incidence of screen detected cases within the study
period, added to the observed clinically detected breast
cancer cases was compared with the expected incidence in
the absence of screening. We estimated the overdiagnosis
first for invasive tumours only, then for all cancers including
DCIS. Overdiagnosis of invasive breast cancer cases was
estimated at 2% (non-significant). The inclusion of in situ
cases in the model increased the risk of overdiagnosis to 5%
(statistically significant), supporting the view that DCIS could
be majorly responsibility for the excess. For the Florence data,
we estimated an excess of incidence for women aged 50 to
84 years at about 15% at short term follow up and 11% at
long term. The excess corrected for lead time was 12% at
short term and 2% at long term. The implications are that an
evaluation of overdiagnosis in the short term of service
screening — when the prevalence screening is mainly
ongoing — can be misleading, and that when long term data
are available, correction for lead time yields a much more
modest estimate of overdiagnosis. These are probably
overestimates of overdiagnosis, using the incidence rates of
1985 to 1989 without consideration for the increasing trend
in breast cancer incidence.
More detailed modelling of overdiagnosis
The possibility of overdiagnosis has been a cause for
concern, in particular with regard to the occurrence of
carcinoma in situ [12]. Detection of in situ lesions is a feature
of mammography screening and natural history and the
probability of progression of this kind of lesion is not fully
understood.
Yen  et al. [13] reviewed the rates of DCIS and invasive
cancers from the Swedish Two County Study and from
various service screening programmes to: derive tentative
estimates of DCIS detection rates that should be typically
observed; describe the typical range of absolute detection
rates of DCIS; and estimate the proportion of DCIS detected
at screening that truly represents overdiagnosis.
They used a six-state Markov Model that fitted the data
reasonably. In their conclusions, 37% of DCIS cases at the
prevalence screening were estimated to be non-progressive;
the corresponding figure at incidence screens was 4%. On
the basis of the estimates, a woman attending for prevalent
screening has a 1 in 3,300 chance of being diagnosed with a
non-progressive DCIS. The probability of being diagnosed
with a progressive DCIS or invasive carcinoma was 1 in 175.
They concluded that there was an element of overdiagnosis of
DCIS in mammographic screening; however, this element is
modest in comparison with the likely benefit of mammography.
The increasing number of DCIS cases poses the challenge to269
therapy to develop treatment protocols taking into account the
potential aggressiveness of the detected lesion.
The increased incidence of DCIS has been found in
randomized controlled trials and service screening to be at
least partly balanced by a later reduction in invasive cancer
incidence [7,14].
This evidence is in contrast with the conclusion of the
International Agency for Research on Cancer (IARC) expert
group, which states “studies of populations…provide no
evidence of a decrease of incidence of invasive cancers”
[15]. The expert group conclusion was based on descriptive
trends from SEER, the US cancer registry network, without
any estimate of the impact of lead time in the excess of the
observed carcinoma in situ incidence. The above results
suggest that where overdiagnosis is explicitly estimated,
taking into account other causes of increased incidence, the
estimate is usually small. There is, however, a need for further
quantification of overdiagnosis from other screening
programmes and more detailed models.
Overtreatment
Overtreatment may be considered to occur in two ways
(although these are related). Firstly, if there are overdiagnosed
cases, any treatment of these is unnecessary. As one cannot
tell when a breast cancer is diagnosed whether it would or
would not progress in the absence of treatment, some
treatment, particularly excision, is inevitable. As noted above,
empirical estimates of overdiagnosis, which take into account
effects of lead time, suggest that the proportion of
overdiagnosed tumours is small, but there is no room for
complacency. To minimise the burden of overtreatment of this
kind, research must continue on tumour biology to further
quantify the aggressive potential of screen-detected cancers,
notably DCIS. In the meantime, treatment should be individually
decided on the basis of the aggressive potential, as detected,
for example, by stage or grade of the lesion diagnosed.
The second major manifestation of overtreatment is the
administration of more aggressive therapies than is necessary
to ‘true’ but very early stage cancers [16,17]. The one-size-
fits-all philosophy of cytotoxic chemotherapy for all invasive
lesions is inappropriate when one considers that node
negative tumours smaller than 10 mm have survival rates in
excess of 90% without chemotherapy. In such cases the
benefits and risks to life of cytotoxic agents may actually have
a negative balance. The first response to this problem should
be to tailor the treatment to the tumour.
There is evidence from the Florence programme that this is
occurring in terms of surgery [18]. With the introduction of the
screening programme, absolute numbers of breast conserving
surgery episodes increased and absolute numbers of
mastectomies fell (Fig. 2). The rates of the two types of
operations paralleled very closely the rates of early and late
stage tumours. There is an onus on the oncological community
to ensure that surgical treatment and adjuvant therapies are
administered on the basis of tumour characteristics.
Conclusion
Overdiagnosis in breast cancer screening is probably a minor
phenomenon, but further quantification is needed from
multiple service screening programmes. Estimates of
overdiagnosis should take into account other causes of
observed excess incidence, such as lead time. The large
numbers of early stage tumours being diagnosed in
screening programmes suggest that care should be taken to
minimise harm from over-aggressive therapy for such lesions.
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Breast conserving surgery and tumour size (<pt2) rates in Florence
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